

**Amendments to the Claims**

Please amend claim 15 as indicated in the listing of claims.

The listing of claims will replace all prior versions, and listings of claims in the application.

**Listing of Claims:**

1.-14. (Canceled).

15. (Currently amended) An isolated antibody that specifically binds to a ~~C-terminal~~ fragment of connective tissue growth factor (CTGF) polypeptide, but not platelet derived growth factor (PDGF), wherein the antibody inhibits DNA synthesis but does not inhibit collagen synthesis, and wherein the ~~C-terminal~~ fragment of CTGF is consists of amino acid residues ~~4 through 74 of SEQ ID NO:4 or 75 through 172 of SEQ ID NO:4.~~

16.-18. (Canceled).

19. (Original) The antibody of claim 15, wherein the antibody is a monoclonal antibody.

20. (Original) The antibody of claim 19, wherein the antibody is a human monoclonal antibody.

21. (Original) The antibody of claim 15, wherein the antibody is a polyclonal antibody.

In re Application of:  
Grotendorst and Neff  
Application No.: 10/658,856  
Filed: September 9, 2003  
Page 5 of 11

PATENT  
Atty Docket No.: FIBRO1130-3

22. (Previously presented) The antibody of claim 15, wherein the antibody is a murine antibody.

23. (Original) A composition comprising the antibody of claim 15 and a pharmaceutically acceptable excipient or carrier.

24.-36. (Canceled).

37. (Previously presented) The antibody of claim 15, wherein the antibody is a humanized antibody.